GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Forward Dividend Yield %

Innate Pharma (Innate Pharma) Forward Dividend Yield % : 0.00% (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Forward Dividend Yield %?

As of today (2024-04-28), the Forward Annual Dividend Yield of Innate Pharma is 0.00%.

As of today (2024-04-28), the Trailing Annual Dividend Yield of Innate Pharma is 0.00%.

IPHA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.56
* Ranked among companies with meaningful Forward Dividend Yield % only.

Innate Pharma's Dividends per Share for the six months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Innate Pharma's Forward Dividend Yield %

For the Biotechnology subindustry, Innate Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Forward Dividend Yield % falls into.



Innate Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Innate Pharma  (NAS:IPHA) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Innate Pharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (Innate Pharma) Business Description

Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.